Gulba D C, Barthels M, Westhoff-Bleck M, Jost S, Rafflenbeul W, Daniel W G, Hecker H, Lichtlen P R
Division of Cardiology, Hannover Medical School, FRG.
Circulation. 1991 Mar;83(3):937-44. doi: 10.1161/01.cir.83.3.937.
It has been suggested that thrombolysis in a feedback reaction may generate pro-coagulant activities.
Fifty-five patients were treated with urokinase-preactivated prourokinase (n = 35) or tissue-type plasminogen activator (n = 20) for acute myocardial infarction and underwent coronary angiography at 90 minutes and at 24-36 hours into thrombolysis, and fibrinogen (Ratnoff-Menzie), D-dimer (ELISA) and thrombin-antithrombin III complex levels (ELISA) were measured. Primary patency was achieved in 39 patients (70.9%), 13 of whom (33.3%) suffered early reocclusion. Nonsignificant decreases in fibrinogen levels were observed while D-dimer levels increased +3,008 +/- 4,047 micrograms/l (p less than 0.01), differences not being significant in respect to the thrombolytic agents or to the clinical course. In contrast, while thrombin-antithrombin III complex levels decreased -4.4 +/- 13.0 micrograms/l in patients with persistent patency, they increased +7.5 +/- 13.6 micrograms/l in case of nonsuccessful thrombolysis (p less than 0.02) and +11.9 +/- 23.8 micrograms/l in case of early reocclusion (p less than 0.001). For patients with thrombin-antithrombin III complex levels greater than 6 ng/l 120 minutes into thrombolysis, the unfavorable clinical course was predicted with 96.2% sensitivity and 93.1% specificity.
Generation of thrombin, occurring during thrombolysis, is a major determinant for the success of therapy and thrombin-antithrombin III levels may serve as predictors for the short-term prognosis.
有观点认为,反馈反应中的溶栓可能会产生促凝血活性。
55例急性心肌梗死患者接受尿激酶预激活的纤溶酶原(35例)或组织型纤溶酶原激活剂(20例)治疗,并在溶栓开始后90分钟以及24 - 36小时进行冠状动脉造影,同时测定纤维蛋白原(Ratnoff - Menzie法)、D - 二聚体(ELISA法)和凝血酶 - 抗凝血酶III复合物水平(ELISA法)。39例患者(70.9%)实现了初始血管通畅,其中13例(33.3%)出现早期再闭塞。纤维蛋白原水平有不显著下降,而D - 二聚体水平升高了3008±4047微克/升(p<0.01),这一差异在溶栓药物及临床病程方面并无显著意义。相比之下,持续血管通畅的患者凝血酶 - 抗凝血酶III复合物水平下降了4.4±13.0微克/升,溶栓未成功的患者该水平升高了7.5±13.6微克/升(p<0.02),早期再闭塞的患者升高了11.9±23.8微克/升(p<0.001)。对于溶栓120分钟时凝血酶 - 抗凝血酶III复合物水平大于6纳克/升的患者,预测不良临床病程的敏感度为96.2%,特异度为93.1%。
溶栓过程中产生的凝血酶是治疗成功的主要决定因素,凝血酶 - 抗凝血酶III水平可作为短期预后的预测指标。